Kolexia
Guidez Stephanie Hématologie
Guidez Stephanie
Hématologie
Hôpital La Miletrie
Poitiers, France
163 Activités
53 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Myélome multiple Lymphome B Maladie de Hodgkin Lymphome folliculaire Lymphome B diffus à grandes cellules Macroglobulinémie de Waldenström Lymphome T Lymphome malin non hodgkinien

Collaborateurs

Voir plus
Leleu Xavier
Leleu Xavier
Hôpital La Miletrie, Poitiers, France
Morschhauser Franck
Morschhauser Franck
Centre Hospitalier de Lille, Lille, France
Gruchet Cecile
Gruchet Cecile
Hôpital La Miletrie, Poitiers, France
Bachy Emmanuel
Bachy Emmanuel
Hôpital Lyon Sud, Pierre-Bénite, France

Industries

Voir plus
A+A
24 collaboration(s)
Dernière en 2023
Janssen
12 collaboration(s)
Dernière en 2023
Gilead
11 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
7 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)
Essai Clinique (Roche)   13 mars 2024
RELEVANCE: A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The "RELEVANCE" Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed.
Essai Clinique (Celgene)   13 mars 2024
MorningLyte: A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
LyMa101: Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
Annals of hematology   06 mars 2024
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   16 février 2024
DALY 2-EU: A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT
Essai Clinique (Miltenyi Biomedicine GmbH)   31 janvier 2024
Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome. A DESCAR-T study.
Blood advances   04 janvier 2024
Study of Lacutamab in Peripheral T-cell Lymphoma: A Randomized Non Comparative Phase II Study of Lacutamab With GemOx Versus GemOx Alone in Relapsed/Refractory Patients With Peripheral T-cell Lymphoma
Essai Clinique (Innate Pharma)   04 décembre 2023
Phase 2 LYSA study of prednisone, vinblastine, doxorubicin, bendamustine for untreated older Hodgkin lymphoma patients.
Blood   18 novembre 2023